DMRA Latest Press Releases

-- November 5, 2026 --

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- November 4, 2026 --

Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights Globe Newswire 4:06 PM

Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting Globe Newswire 9:00 AM

-- October 2, 2026 --

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:59 AM

-- September 3, 2026 --

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 8:00 AM

-- August 10, 2026 --

Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Globe Newswire 4:05 PM

-- August 5, 2026 --

Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis Globe Newswire 8:00 AM

-- August 3, 2026 --

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- July 17, 2026 --

Damora Announces Redomestication from Delaware to Cayman Islands Globe Newswire 8:00 AM

-- July 1, 2026 --

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes